KelunPharma

Kelun-Biotech is a China-based innovative biopharmaceutical company focused on discovery, development, manufacturing, and commercialization of biologics and small molecules, with particular strength in antibody-drug conjugates. The company is a holding subsidiary of Kelun Pharmaceutical and has built integrated R&D, clinical, and manufacturing capabilities, supported by ADC, biologics, and small-molecule technology platforms. Its lead franchise is centered on sacituzumab tirumotecan, a TROP2-directed ADC that has achieved multiple regulatory approvals in China, while additional assets span HER2, Claudin 18.2, Nectin-4, RET, PD-L1, TSLP, and other targets. Kelun-Biotech also partners globally with companies including Merck, Harbour BioMed, Ellipses Pharma, and Crescent Biopharma to expand development and commercialization outside Greater China. The company is publicly listed in Hong Kong and positions itself as an oncology-led innovator with growing activity in immunology and other serious diseases.